SCHEMBL205605

SCHEMBL205605

CN(CCc1c[nH]c2ccccc12)C(=O)CCC(=O)NC1CCC(Cc2cccc(Cl)c2)(N(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.50
BCHE P06276 1/20 0.50
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
CDK4 P11802 9/20 0.45
CCND1 P24385 8/20 0.45
SIGMAR1 Q99720 1/20 0.44
NPC1 O15118 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RAB9A P51151 1/20 0.42
MC4R P32245 1/20 0.40
MC3R P41968 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208032 0.92 CDK4 (0.50) ACHEBCHEHPGDHTTRECQL
SCHEMBL251054 0.92 HPGD (0.52) ACHEBCHEHPGDHTTRECQL
SCHEMBL206020 0.89 ACHE (0.53) ACHEBCHEHPGDHTTRECQL
SCHEMBL205896 0.88 HPGD (0.52) ACHEBCHEHPGDHTTRECQL
SCHEMBL5481666 0.84 MC4R (0.46) ACHEBCHEHPGDHTTRECQL
SCHEMBL205653 0.81 SIGMAR1 (0.48) HPGDHTTSIGMAR1NPC1RAB9A
SCHEMBL207608 0.81 BCHE (0.56) ACHEBCHEHPGDHTTRECQL
SCHEMBL207809 0.80 HPGD (0.53) ACHEBCHEHPGDHTTRECQL
SCHEMBL207618 0.80 OPRL1 (0.62) ACHEBCHEHPGDHTTRECQL
SCHEMBL206862 0.78 EPHX2 (0.43) HPGDHTTSIGMAR1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD ACHE 2158/4885BCHE 894/4885HPGD 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.